Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07154511 · ClinicalTrials.gov registry record · Phase 1

Phase 2 Trial of Tributyrin in People With Parkinson's Disease and Cognitive Impairments

A Phase 1 study of Parkinson Disease and Parkinson Disease Dementia, sponsored by Prabesh Kanel.

Recruiting
Registry status
Phase 1
Development phase
45
Enrollment target
1
Study location

NCT07154511 is a Phase 1 study of Parkinson Disease and Parkinson Disease Dementia that is actively recruiting participants, run by Prabesh Kanel. The registered enrollment target is 45 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07154511, a Phase 1 study of Parkinson Disease and Parkinson Disease Dementia, is actively recruiting participants, sponsored by Prabesh Kanel.

RECRUITING
Registry status
Phase 1
Development phase
45 participants
Enrollment target
1
Study location

Study Summary

The goal of this clinical trial is to learn if taking a tributyrin supplement works to improve memory and thinking and walking and balance in adults with Parkinson disease Parkinson disease dementia. It will also learn about the safety of tributyrin supplementation. The main questions it aims to answer are: 1. Does tributyrin improve memory/thinking test scores and walking/balance ability? 2. What medical problems do participants have when taking tributyrin? Researchers will compare tributyrin to a placebo (a look-alike substance that contains no drug) to see if tributyrin works to treat Parkinson disease symptoms. Participants will: 1. Take tributyrin 3 times a day for 80-100 days 2. Complete motor and cognitive testing at the clinic before and after the supplementation period 3. Complete brain imaging (MRI scans and PET scans) before and after the supplementation period.

Conditions Studied

Parkinson Disease Parkinson Disease Dementia

Interventions

  • DRUG Placebo
  • DRUG Tributyrin

Study Locations (1)

Michigan

  • Domino's Farms - Ann Arbor

Trial Details

FieldValue
Enrollment Target 45 participants
Start Date 2025-11-07
Est. Completion 2027-05
Phase Phase 1

Sponsor

Prabesh Kanel

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07154511

The ClinicalTrials.gov registry entry for NCT07154511 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (99% lower). The listed sponsor is Prabesh Kanel, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Parkinson Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT07154511 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.

Frequently Asked Questions

What is clinical trial NCT07154511 about?

NCT07154511 is a clinical study titled "Phase 2 Trial of Tributyrin in People With Parkinson's Disease and Cognitive Impairments". The goal of this clinical trial is to learn if taking a tributyrin supplement works to improve memory and thinking and walking and balance in adults with Parkinson disease Parkinson disease dementia. It will also learn about the safety of tributyrin supplementation. The main questions it aims to ans...

What is the current status of trial NCT07154511?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2025-11-07. Estimated completion is 2027-05.

What conditions does trial NCT07154511 study?

This clinical trial studies the following conditions: Parkinson Disease, Parkinson Disease Dementia.

What interventions are being tested in trial NCT07154511?

The interventions under investigation include: Placebo (DRUG), Tributyrin (DRUG).

Who is sponsoring clinical trial NCT07154511?

This trial is sponsored by Prabesh Kanel, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07154511 being conducted?

This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Parkinson Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Parkinson Disease

All registered trials for this condition

Parkinson Disease Dementia

All registered trials for this condition

Michigan

All trials with a study site in Michigan

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.